What’s New in Susceptibility Testing of Mycobacteria
You must log in to register
- Non-member - $30
- Individual Student - $30
- Individual Associate - $30
- Individual Full Member - $30
- Industry Level III - $30
- Industry Level II - $30
- Industry Level I - $30
- HCPGOV Level III - $30
- HCPGOV Level II - $30
- HCPGOV Level I - $30
- Health System - $30
- CLSI Staff - Free!
Susceptibility testing of mycobacteria will be discussed in this upcoming webinar. Speakers will:
- Discuss current methods for phenotypic and genotypic antimicrobial susceptibility testing (AST) of Mycobacterium tuberculosis complex (MTBC).
- Review new and evolving standards for non-tuberculous Mycobacterium spp.
- Evaluate updated guidance from the forthcoming CLSI Standard M24.
- Review recent changes that impact AST for MTBC.
Barbara A. Brown-Elliott MS, MT(ASCP), SM
Professor of Microbiology and Associate Director of the Mycobacteria/Nocardia Laboratory at the University of Texas Health Science Center at Tyler (UTHSCT)
University of Texas Health Science Center at Tyler (UTHSCT)
Barbara A. Brown-Elliott MS, MT(ASCP), SM is currently a Professor of Microbiology and Associate Director of the Mycobacteria/Nocardia Laboratory at the University of Texas Health Science Center at Tyler (UTHSCT). She has supervised the UTHSCT laboratory since 1988. Before coming to the UTHSCT, she served as a clinical microbiology supervisor, a consultant for a clinical microbiology reference laboratory, and a microbiology Adjunct Professor in medical technology. She is the author and/or co-author of more than 300 peer-reviewed articles and chapters on nontuberculous mycobacteria (NTM), Nocardia and other aerobic actinomycetes, with over 100 publications on antimicrobial susceptibility testing and resistance mechanisms. She has been a member of the American Society for Microbiology (ASM) since 1978 and is a frequent speaker at local, national, and international meetings. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antimycobacterial Susceptibility Subcommittee (Currently revised as the Antimycobacterial Susceptibility Working Group). She is a 2009 recipient of the Becton Dickinson Gardner Middlebrook Award for Outstanding Work in Mycobacteriology, the ASM Scherago-Rubin Award for outstanding clinical microbiologist in 2013, and an ASM Distinguished Lecturer from 2019-2020.
Marie-Claire Rowlinson, PhD, D(ABMM)
Chief of Bacterial Diseases at the Wadsworth Center, New York State Department of Health
Wadsworth Center, New York State Department of Health
Dr. Marie-Claire Rowlinson received her undergraduate and doctoral degrees in Medical Microbiology in the UK and then completed a post-doctoral fellowship in Medical and Public Health Laboratory Microbiology at University of California, Los Angeles. Following the fellowship, Dr. Rowlinson worked with the Association of Public Health Laboratories (APHL) in their Global Health program, building laboratory capacity in Eastern Europe, Africa, and the Caribbean. From 2012 to 2021, she held the position of Assistant Laboratory Director and CLIA Laboratory Director at the Florida Department of Health, Bureau of Public Health Laboratories in Jacksonville. Since September 2021, Dr. Rowlinson is the Chief of Bacterial Diseases at the Wadsworth Center, New York State Department of Health. Dr. Rowlinson’s expertise is in infectious disease diagnostics, in particular molecular diagnostics, tuberculosis, and global health. She continues to work closely with the Association of Public Health Laboratories and is the Chair of the APHL Infectious Diseases Committee and a Member of the TB Subcommittee. She also continues to work with APHL on an international level, consulting with the Global Health program, most recently working with the Ukraine Ministry of Health. Dr. Rowlinson is a Member of the College of American Pathologists Microbiology Committee.
Romney Humphries, PhD D(ABMM) (Moderator)
Director of Infectious Diseases Laboratories and Director of the Division of Laboratory Medicine, Vanderbilt University Medical Center
Vanderbilt University Medical Center
Romney Humphries, PhD D(ABMM) is a Professor in the Department of Pathology, Microbiology and Immunology at Vanderbilt University Medical Center, where she is the Director of Infectious Diseases Laboratories and the Director of the Division of Laboratory Medicine.
Romney received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA.
She worked at UCLA as an assistant professor in Pathology and laboratory medicine from 2010–2017 and was the section chief for clinical microbiology from 2012–2017. She then took on the role of Chief Scientific Officer at Accelerate Diagnostics from 2017–2020 before returning to academia in 2020, at VUMC.
Dr. Humphries is passionate about clinical microbiology and antimicrobial resistance in particular. She is a champion for the development of novel diagnostic tests for infectious diseases to transform how patients with infections are managed.
Dr. Humphries is an editor for the Journal of Clinical Microbiology and Clinical Infectious Diseases. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antibiotic Susceptibility Testing (AST) Subcommittee, the College of American Pathologists (CAP) Microbiology Committee, the American Society for Microbiology (ASM) Professional Practices Committee, and vice-chair of the Infectious Diseases Society of America Diagnostics Committee.
She is the author of over 150 peer-reviewed articles, numerous book chapters, and has lectured globally on the topics of antimicrobial resistance and diagnostic microbiology. Dr. Humphries is the 2022 ASM awardee for Leadership and Research in Clinical Microbiology. She is a fellow of the American Academy of Microbiology, and the Infectious Diseases Society of America.